1 minute read
SYNER-TOX and The Ship of The Desert
The camel occupies a distinguished place in the heritage of the Arabs, a position dating back nearly 1800 years. We raise camels as companions and for meat, milk, transportation, and racing. So many of us depended on their ability to live in the desert and adapt to its harsh nature… intense heat, scarcity of water, and scorching sun. In the United Arab Emirates, the population of camels today is approximately 450,000.
For this reason, the camel has a special place in the Middle East and needs special medical care from birth and during its 40-year life span.
Advertisement
SYNER-TOX has been used in camels in the gulf region for more than a decade now with a significant impact on the camel’s health, not only with mycotoxins but especially with blood parasite/bacterial infections as there can be high occurrence of such blood infections in local camels caused by Anaplasma (bacterial), Theileria (parasitic), Trypanosoma (parasitic), and Babesia (parasitic). The diseases are characterized by fever and intravascular hemolysis leading to progressive anemia, hemoglobinuria, and jaundice, as well as ‘off feed’, and may result in death.
The elevated liver enzymes, especially AST (aspartate aminotransferase), are very high which indicates liver damage not only from blood parasites but also from excessive drug detoxifications and mycotoxins. Using SYNER-TOX as a supportive treatment for successive three to five days with an oral dose twice daily of 60 – 75 ml diluted in 2 Liters of water showed remarkable improvement in reducing AST back to normal protecting the camel’s liver from damage and potential death.
SYNER-TOX now is the main supportive treatment for camels especially in liver disease having gained full trust of owners based on the liver recovery and health vitality of camels after treatment with it.
Syner-Tox is a liquid product added to drinking water. Syner-Tox uses Agrarian Solutions’ proprietary L-Form technology found in Select BioCycle and Select DTX.
Written By: John Doerr, Ph.D., PAS, Dpl. ACAP Vice President, Science & Technology
